Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Chaudhary, Ajay Kumar ^a,b   Singh, Mamta ^b   Bharti, Alok C ^c   Asotra, Kamlesh ^d   Sundaram, Shanthy ^a   Mehrotra, Ravi ^b  

^a UNIVERSITY OF ALLAHABAD   (India)

^b MLN MEDICAL COLLEGE   (India)

^c Division of Molecular Oncology   (India)

^d University of California Office of President Oakland   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; BATIMASTAT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BMS 2755291; CGS 27023A; COLLAGENASE 3; GELATINASE A; GELATINASE B; INCYCLINIDE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PEPTIDOMIMETIC AGENT; PRINOMASTAT; SOLIMASTAT; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CANCER DIAGNOSIS; CANCER PATIENT; CHROMOSOMAL LOCALIZATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; TREATMENT DURATION; ANIMAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; NEOVASCULARIZATION (PATHOLOGY);

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, GENETIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77949445888     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-10     Document Type: Review

References (84)

1. American Cancer Society Inc 2008. http://www.cancer.org/doc root/STT/content/STT-1x-Cancer-Facts-and-Figures-2008.asp
2. Squamous cell carcinomas of the head and neck. RJ Sanderson JA Ironside, BMJ 2002 325 822 27 10.1136/bmj.325.7368.822 12376446 (Pubitemid 35177978)
3. Prevalence of oral pre-malignant and malignant lesions at a tertiary level hospital in Allahabad, India. R Mehrotra S Pandya AK Chaudhary M Kumar M Singh, Asian Pac J Cancer Prev 2008 9 2 263 65 18712970
4. Role of tobacco in the development of head and neck squamous cell carcinoma in an eastern Indian population. R Basu S Mandal A Ghosh TK Poddar, Asian Pac J Cancer Prev 2008 9 3 381 86 18990006
5. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. K Strati HC Pitot PF Lambert, Proc Natl Acad Sci 2006 103 38 14152 157 10.1073/pnas.0606698103 16959885 (Pubitemid 44452995)
6. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. YA DeClerck AM Mercurio MS Stack HA Chapman MM Zutter RJ Muschel, Am J Pathol 2004 164 4 1131 39 15039201
7. Extra cellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. WG Stetler-Stevenson LA Liotta DE Kleiner, Faseb J 1993 7 1434 41 8262328 (Pubitemid 24003262)
8. Matrix metalloproteinases. H Nagase JF Woessner, J Biol Chem 1999 274 21491 494 10.1074/jbc.274.31.21491 10419448 (Pubitemid 129519680)
9. Proteases in invasion: matrix metalloproteinases. WG Stetler-Stevenson AE Yu, Semin Cancer Biol 2001 11 143 52 10.1006/scbi.2000.0365 11322833
10. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. DE Gomez DF Alonso H Yoshiji UP Thorgeirsson, Eur J Cell Biol 1997 74 111 22 9352216 (Pubitemid 27455388)
11. Tissue inhibitors of metalloproteases: regulation and biological activities. G Fassina N Ferrari C Brigati R Benelli L Santi DM Noonan, Clin Exp Metastasis 2000 18 111 20 10.1023/A:1006797522521 11235986 (Pubitemid 32165244)
12. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. T Turpeenniemi-Hujanen, Biochimie 2005 87 287 97 10.1016/j.biochi.2005.01.014 15781315 (Pubitemid 40387607)
13. Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. HC Lai CM Chu YW Lin CC Chang S Nieh MH Yu TY Chu, Gynecol Oncol 2005 96 2 314 9 10.1016/j.ygyno.2004.09.065 15661214 (Pubitemid 40127127)
14. A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Y Nishioka S Sagae A Nishikawa S Ishioka R Kudo, Cancer Lett 2003 200 1 49 55 10.1016/S0304-3835(03)00411-7 14550952 (Pubitemid 37222358)
15. Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. LM Baltazar-Rodriguez A Anaya-Ventura M Andrade-Soto EA Monrroy-Guizar JR Bautista-Lam G Jonguitud-Olguin, et al. Biochem Genet 2008 46 3-4 137 44 10.1007/s10528-007- 9136-4 18210196
16. MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer. H Singh M Jain B Mittal, Gynecol Oncol 2008 110 1 71 75 10.1016/j.ygyno.2008.03. 007 18448157
17. Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. P McColgan P Sharma, Int J Cancer 2009 125 6 1473 78 10.1002/ijc.24441 19507256
18. The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in Chinese. Y Li JH Jia S Kang XJ Zhang J Zhao N Wang RM Zhou DL Sun YN Duan DJ Wang, Int J Gynecol Cancer 2009 19 1 129 33 19258954
19. Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Y Li DL Sun YN Duan XJ Zhang N Wang RM Zhou ZF Chen SJ Wang, Mol Biol Rep 2010 37 1 197 205 10.1007/s11033-009-9593-4 19562509
20. Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies. B Peng L Cao W Wang L Xian D Jiang J Zhao Z Zhang X Wang L Yu, Mutagenesis 2010 25 1 41 8 10.1093/mutage/gep041 19843588
21. How matrix metalloproteinases regulate cell behavior. MD Sternlicht Z Werb, Annu Rev Cell Dev Bio 2001 17 463 16 10.1146/annurev.cellbio.17.1.463 (Pubitemid 33096184)
22. Strategies for MMP inhibition in cancer: innovations for the post-trial era. CM Overall C Lopez-Otin, Nat Rev Cancer 2002 2 657 72 10.1038/nrc884 12209155 (Pubitemid 37328917)
23. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. R Visse H Nagase, Circ Res 2003 92 827 39 10.1161/01.RES.0000070112.80711.3D 12730128 (Pubitemid 36542523)
24. Matrix metalloproteinases and tumor progression. JM Freije M Balbin AM Pendas LM Sanchez XS Puente C Lopez-Otin, Adv Exp Med Biol 2003 532 91 107 12908552 (Pubitemid 37176782)
25. Regulation of matrix metalloproteinase expression in tumour invasion. J Westermarck V-M Kahari, FASE 1999 13 781 92 (Pubitemid 29220691)
26. Matrix metalloproteinases: a review. H Birkedal-Hansen WG Moore MK Bodden LJ Windsor B Birkedal-Hansen A DeCarlo, Crit Rev Oral Biol Med 1993 4 197 250 8435466 (Pubitemid 23103292)
27. Tissue inhibitors of metalloproteinases: evolution, structure and function. K Brew D Dinakapandian H Nagase, Biochim Biophys Acta 2000 1477 267 83 10708863 (Pubitemid 30119906)
28. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. H Uzui A Harpf M Liu TM Doherty A Shukla N Chai, Circulation 2002 106 24 3024 30 10.1161/01.CIR.0000041433.94868.12 12473546 (Pubitemid 35440283)
29. Control of matrix metalloproteinase catalytic activity. HJ Ra WC Parks, Matrix Biol 2007 26 587 596 10.1016/j.matbio.2007.07.001 17669641
30. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. S Ye, Matrix Biol 2000 19 7 623 639 10.1016/S0945-053X(00)00102-5 11102751
31. Type I collagen degradation by invasive oral squamous cell carcinoma. BL Ziober MA Turner JM Palefsky MJ Banda RH Kramer, Oral Oncol 2000 36 4 365 72 10.1016/S1368-8375(00)00019-1 10899676 (Pubitemid 30427258)
32. Matrix metalloproteinase in tumor progression: focus on basal and squamous cell skin cancer. E Kerkela U Saarialho-Kere, Exp Dermatol 2003 12 109 125 10.1034/j.1600-0625.2003.120201.x 12702139 (Pubitemid 36934696)
33. Interstitial collagenases as marker of tumor progression. CE Brinckerhoff JL Rutter U Benbow, Clin Cancer Res 2000 6 4823 4830 11156241 (Pubitemid 32110426)
34. Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. M Woo K Park J Nam JC Kim, J Gastroenterol Hepatol 2007 22 7 1064 70 10.1111/j.1440-1746.2006.04424.x 17608852 (Pubitemid 47019841)
35. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. AI Tasci V Tugcu B Ozbay A Simsek V Koksal, BJU Int 2008 101 503 507 17986285
36. A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer. Y Shimizu S Kondo A Shirai M Furukawa T Yoshizaki, Auris Nasus LarynxLarrynx 2008 35 381 389 10.1016/j.anl.2007.12.002
37. The 2G allele of promoter region of Matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. R Nishizawa M Nagata AA Noman N Kitamura H Fujita H Hoshina, BMC Cancer 2007 7 187 10.1186/1471-2407-7-187 17919326 (Pubitemid 350162827)
38. Matrix metalloproteinase-1 (-1607) 1G/2G and -9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas. HB Nasr S Mestiri K Chahed N Bouaouina S Gabbouj M Jalbout, Clin Chim Acta 2007 384 57 63 10.1016/j.cca.2007.05.018 17599818 (Pubitemid 47247410)
39. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. JL Rutter TI Mitchell G Buttice J Meyers JF Gusella LJ Ozelius, Cancer Res 1998 58 5321 5325 9850057 (Pubitemid 28551108)
40. Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. GB Tower CC Coon U Benbow MP Vincenti CE Brinckerhoff, Biochim Biophys Acta 2002 1586 3 265 74 11997078 (Pubitemid 34457921)
41. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population. ZG Cao CZ Li, Oral Oncol 2006 42 1 32 8 10.1016/j.oraloncology.2004. 08.015 16256416
42. Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. F Zinzindohoué H Blons S Hans MA Loriot AM Houllier D Brasnu, Anticancer Res 2004 24 3b 2021 6 15274394 (Pubitemid 38954627)
43. Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. E Vairaktaris C Yapijakis S Derka Z Serefoglou S Vassiliou E Nkenke, Anticancer Res 2007 27 1A 459 64 17352267 (Pubitemid 46363366)
44. Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. T Hashimoto K Uchida N Okayama Y Imate Y Suehiro Y Hamanaka, Cancer Lett 2004 211 1 19 24 10.1016/j.canlet.2004. 01.032 15194213 (Pubitemid 38759765)
45. Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. T Salo LA Liotta K Tryggvason, J Biol Chem 1983 258 3058 3063 6298220
46. Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin. M Höyhtyä T Turpeenniemi-Hujanen W Stetler-Stevenson H Krutzsch K Tryggvason LA Liotta, FEBS Lett 1988 233 1 109 113 10.1016/0014-5793(88)81365-6 2838321
47. Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. G Murphy R Ward RM Hembry JJ Reynolds K Kuhn K Tryggvason, Biochem J 1989 258 463 72 2539808
48. Matrix metalloproteinases and their inhibitors in connective tissue remode-ling. JF Woessner, Faseb J 1991 5 2145 54 1850705
49. Matrix metalloproteinases: biologic activity and clinical implications. AR Nelson B Fingleton ML Rothenberg LM Matrisian, J Clin Oncol 2000 18 135 1149 (Pubitemid 30123793)
50. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. SJ Price DR Greaves H Watkins, J Biol Chem 2001 276 7549 58 10.1074/jbc.M010242200 11114309 (Pubitemid 37392068)
51. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. P O-Charoenrat P Khantapura, Oral Oncol 2006 42 3 257 67 10.1016/j.oraloncology.2005.07.008 16275157 (Pubitemid 43246757)
52. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. SC Lin SS Lo CJ Liu MY Chung JW Huang KW Chang, J Oral Pathol Med 2004 33 7 405 9 10.1111/j.1600-0714.2004.00231.x 15250832
53. Stromelysin-1 (MMP-3) is inducible in T lymphoma cells and accelerates the growth of lymphoid tumors in vivo. C Van Themsche EF Potworowski Y ST-Pierre, Biochem Biophys Res Commun 2004 315 884 91 10.1016/j.bbrc.2004.01.144 14985095 (Pubitemid 38249386)
54. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. G Ghilardi ML Biondi M Caputo S Leviti M DeMonti E Guagnellini, Clin Cancer Res 2002 8 3820 23 12473595 (Pubitemid 35424775)
55. Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. E Vairaktaris C Yapijakis S Derka Z Serefoglou S Vassiliou E Nkenke, Anticancer Res 2007 27 1A 459 64 17352267 (Pubitemid 46363366)
56. The functional (-1171 5A-6A) polymorphisms of matrix metallopritenase-3 gene as a risk factor for oral submucous fibrosis among male areca users. HF Tu CJ Lui CH Chang J Liu J Li Z Li, J oral Pathol Med 2006 35 99 103 10.1111/j.1600-0714.2006.00370.x 16430740
57. Synergistic effect of stromelysin-1 (Matrix Metallo-Proteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head-neck lesions. AK Chaudhary M Singh AC Bharti M Singh S Shukla AK Singh R Mehrotra, BMC Cancer 2010
58. Human macrophages synthesize and secrete a major 95,000- dalton gelatin-binding protein distinct from fibronectin. T Vartio T Hovi A Vaheri, J Biol Chem 1982 257 8862 8866 7047529
59. The matrix metalloproteinases and their inhibitors. G Murphy AJ Docherty, Am J Respir Cell Mol Biol 1992 7 120 125 1497900
60. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B. JP Witty SA Foster GP Stricklin LM Matrisian PH Stern, J Bone Miner Res 1996 11 72 78 10.1002/jbmr.5650110111 8770699
61. Tumour Necrosis Factor Alpha-308 gene locus Promoter Polymorphism: An Analysis of Association with Health and Disease. MM Elahi K Asotra BM Matata SS Mastana, Biochim Biophys Acta 2009 1792 3 163 72 19708125
62. Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. J Wu L Zhang H Luo Z Zhu C Zangh Y Hou, DNA Cell Biol 2008 27 10 553 7 10.1089/dna.2008.0732 18680431
63. Functional -1562 C-to -T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. HF Tu CH Wu SY Kao CJ Liu TY Liu MT Lui, J Oral Pathol Med 2007 36 409 14 17617834
64. A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. E Vairaktaris S Vassiliou E Nkenke Z Serefoglou S Derka C Tsigris, Eur J Surg Oncol 2008 34 4 450 55 17498910
65. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. E Vairaktaris Z Serefoglou D Avgoustidis C Yapijakis E Critselis A Vylliotis S Spyridonidou S Derka S Vassiliou E Nkenke E Patsouris, Oral Oncol 2009 45 3 247 53 10.1016/j.oraloncology.2008.05.003 18674955
66. TIMPs as multifacial proteins. E Lambert E Dasse B Haye E Petitfrere, Crit Rev Oncol Hematol 2004 49 187 98 10.1016/j.critrevonc.2003.09.008 15036259 (Pubitemid 38251351)
67. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. YA DeClerck N Perez H Shimada TC Boone KE Langley, Cancer Res 1992 52 701 08 1732058
68. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. SS Apte MG Mattei BR Olsen, Genomics 1994 19 86 90 10.1006/geno.1994.1016 8188246
69. Cloning of the human tissue inhibitor of metalloproteinase-4 gene (TIMP4) and localization of the TIMP-4 and Timp4 genes to human chromosome 3p25 and mouse chromosome 6, respectively. TM Olson S Hirohata J Ye K Leco MF Seldin SS Apte, Genomics 1998 51 148 51 10.1006/geno.1998.5362 9693046 (Pubitemid 28373386)
70. Therapeutic developments in matrix metalloproteinase inhibition. PK Shah DJ Wilkin TM Doherty H Uzui TB Rajavashisth A Asotra, Expert Opin Ther Pat 2002 12 5 665 707 10.1517/13543776.12.5.665 (Pubitemid 34537679)
71. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB94) in patients with advanced cancer. S Wojtowicz-Praga J Low J Marshall E Ness R Dickson J Barter, Invest New Drugs 1996 14 193 202 10.1007/BF00210790 8913840 (Pubitemid 26340688)
72. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. VM Macaulay KJ O'Byrne MP Saunders JP Braybrooke L Long, Clin Cancer Res 1999 5 513 20 10100701 (Pubitemid 29131959)
73. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant as cites. GJ Beattie JF Smyth, Clin Cancer Res 1998 4 1899 902 9717817
74. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. A Kruger R Soeltl I Sopov, Cancer Res 2001 61 1272 75 11245418 (Pubitemid 34292540)
75. Development of matrix metalloproteinase inhibitors in cancer therapy. M Hidalgo SG Eckhardt, J Nat Cancer Int 2001 93 178 93 10.1093/jnci/93.3.178 (Pubitemid 32166488)
76. Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196. JA Sparano P Bernardo P Stephenson WJ Gradishar JN Ingle S Zucker, J Clin Oncol 2004 22 23 4683 4690 10.1200/JCO.2004.08.054 15570070 (Pubitemid 41185077)
77. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. GM Tierney NR Griffin RC Stuart H Kasem KP Lynch JT Lury, Eur J Cancer 1999 35 4 563 68 10.1016/S0959-8049(99)00007-6 10492628 (Pubitemid 29192963)
78. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Co-operative Oncology Group trial E2196. S Zucker M Wang JA Sparano WJ Gradishar JN Ingle NE Davidson, Clin Breast Cancer 2006 6 6 525 29 10.3816/CBC.2006.n.006 16595036
79. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. EK Rowinsky R Humphrey LA Hammond, J Clin Oncol 2000 18 178 86 10623708 (Pubitemid 30036351)
80. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. NC Levitt FA Eskens KJ O'Byrne, Clin Cancer Res 2001 7 1912 22 11448904 (Pubitemid 32994825)
81. AE-941 (Neovastat) induces endothelial cell apoptosis through activation of caspase-3 activity. [abstract#3891]. D Gingras N Mousseau M-F Gaumount-Leclerc, Proc AACR 92nd Annual Meeting 2001 42 724
82. A phase I clinical trial of oral Col-3, a matrix metalloproteinase inhibitor, administered daily in patients with refractory metastasis cancer [abstract]. M Rodek W Figg V Dyer W Dahut M Turner S Steinburg, Proc Am Assoc Cancer Res 2000 41 612
83. MMP inhibition and down regulation by biphosphonates. O Teronen P Heikkila YT Konttinen, Ann NY Acad Sci 1999 878 453 65 10.1111/j.1749-6632.1999. tb07702.x 10415748
84. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from deregulation by plasmin is reversed by divalent cation chelator EDTA and the biphosphonate alendronate. AR Farina A Tacconelli A Teri, Cancer Res 1998 58 2957 60 9679953 (Pubitemid 28335069)